Skip to main content

Advertisement

Table 1. Genomic alterations described in high-grade serous ovarian cancer (HGSOC, accounting for 75% of epithelial ovarian cancers)

From: The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

Alteration type Selected genomic alterations and frequency in HGSOC
Defective homologous recombination (occurs in roughly 50% of HGSOC) Germline BRCA mutation (10%–15%)
Somatic BRCA mutation (5%)
BRCA promoter hypermethylation (10%–15%)
EMSY amplification (5%–15%)
RAD51 loss (<5%)
ATM/ATR mutation (3%)
Fanconi gene mutations (5%)
Oncogenic amplifications MAPK (25%)
PIK3CA (20%)
CCNE (20%)
KRAS (11%)
RICTOR (6%)
AKT1, AKT2, or AKT3 (15%)
RAPTOR (4%)
ERBB3 (4%)
ERBB2 (3%)
IGF-1R (3%)…
Oncogenic loss PTEN (7%)
Oncogenic mutations EGFR (4%–9%)
PIK3CA (3%)
PDGFR (4%)
KIT (3%)
ERBB2 (1%)…
  1. The results shown here are in whole or part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov/).